Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Named Ion Torrent CSP

NEW YORK (GenomeWeb News) – Asuragen today said that it has been named a certified service provider for Ion Torrent's Personal Genome Machine.

Austin, Texas-based Asuragen will use the Ion Torrent platform to provide targeted DNA mutation analysis of tumor samples to identify known and de novo mutations within FFPE and FNA specimens. The services will include both Asuragen's SuraSeq custom cancer panels and the Ion AmpliSeq cancer panel.

The CSP program is designed to assure customers that Asuragen has been trained and tested by Life Technologies' Ion Torrent business in the use of the semiconductor-based sequencing technology.

"The PGM next-generation sequencing allows us to expand our proven platform of molecular sample interrogation to assist our customers in their targeted drug and diagnostic development programs," Carol Berry, SVP and GM of Asuragen's Pharmacogenomic Services Division, said in a statement.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.